EMA updates Questions and Answers Document
The European Medicines Agency (EMA) provides answers to frequently asked questions on Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) on its website. These have been compiled and agreed by the GMP/GDP Inspectors Working Group.
This Q&A guidance provides additional interpretation of the European Union (EU) GMP Guidelines and GDP Guidelines published by the European Commission. The list is regularly supplemented or updated. Currently, the legal requirements for veterinary medicinal products have been newly regulated in the EU. To this end, the previously applicable Directive 2001/82/EC - EU Codex for Veterinary Medicinal Products will be repealed on 28 January 2022 and replaced by Regulation (EU) 2019/6. This regulation includes provisions on authorisation, post-authorisation measures, manufacture, import, export, supply and use of veterinary medicinal products, as well as restrictions and sanctions. Accordingly, the questions and answers have now been updated.
The new chapter deals with requirements for active substances that are used as starting materials for the manufacture of veterinary medicinal products. The following questions, among others, are answered:
- Do active substances used as starting materials in veterinary medicinal products have to comply with the same GMP requirements for active substances (for human medicinal products)?
- Are there new obligations regarding active substances for the manufacture of veterinary medicinal products?
- Is a GMP certificate mandatory and how is it issued?
- What applies in the case of inspections?
Related GMP News
02.11.2026Singapore Added to the List of Recognised third Countries for Importation of APIs
02.11.2026Failed GMP Training in 2026: Further GMP Training Deficiencies in FDA Warning Letters
21.10.2026Switzerland: GMP Compliance by Foreign Manufacturers
14.10.2026EU Pharma Package: Council Adopts New Rules
14.10.2026ICH Publishes New Training Material for Quality Guidelines
14.10.2026WHO issues Draft Guidance on Quality Risk Management



